IVERIC bio
- Company typePublic
- Founded2007
- HeadquartersPrinceton, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
IVERIC bio firmographics
Firmographics- Name
- IVERIC bio
- Legal name
- Iveric Bio
- Website
- https://ivericbio.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
IVERIC bio industry classification
Industry- Product category
- Ophthalmic Biopharmaceuticals
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
- akta.pro secondary industries
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Retina & Vitreous Specialists (HLAKAKAE)
Keywords
Where IVERIC bio is headquartered
LocationHeadquarters
- HQ city
- Princeton
- HQ country
- United States
- HQ region
- North America
Markets served
IVERIC bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical Product Sales: Revenue generated from sales of prescription pharmaceutical products, specifically Zimura (avacincaptad pegol) for geographic atrophy. The company prepared for commercial launch contingent on FDA approval, targeting the U.S. market through specialty pharmacy and physician administration channels.
Go-to-market motion1 record
Distribution channels1 record
IVERIC bio product offering
Product offeringCore offering
IVERIC bio developed Zimura (avacincaptad pegol), a novel complement C5 inhibitor administered via intravitreal injection for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The drug targets the complement pathway to reduce photoreceptor degeneration and slow progressive, irreversible vision loss. IVERIC bio was preparing for commercial launch of Zimura in the United States, contingent on FDA regulatory approval.
Product overview
Iveric Bio was a pharmaceutical company focused on developing Zimura, an investigational drug for geographic atrophy (GA), an advanced form of dry age-related macular degeneration. The company pursued regulatory approval for Zimura in the United States with plans for commercial launch, funded in part by debt financing agreements. As of the available source data, Iveric Bio has been acquired by Astellas Pharma Inc.
Differentiator
Problem solved
Functional benefit
Products and services
- Zimura (avacincaptad pegol)
Companies that use IVERIC bio
Customer profileSegments1 record
Ideal customer profiles1 record
IVERIC bio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
IVERIC bio partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights5 records
IVERIC bio competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
IVERIC bio social profiles
Digital presenceIVERIC bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
IVERIC bio leadership team
Management profileNumber of profiles
Profiles9 records
IVERIC bio funding detail
Funding detailFunding overview
Funding rounds11 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IVERIC bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IVERIC bio
What does IVERIC bio do?
IVERIC bio developed Zimura (avacincaptad pegol), a novel complement C5 inhibitor administered via intravitreal injection for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The drug targets the complement pathway to reduce photoreceptor degeneration and slow progressive, irreversible vision loss. IVERIC bio was preparing for commercial launch of Zimura in the United States, contingent on FDA regulatory approval.
Is IVERIC bio a public or private company?
IVERIC bio is a public company. It is classified as corporate owned and is currently acquired.
When was IVERIC bio founded?
IVERIC bio was founded in 2007. It employs 101 to 250 people.
Where is IVERIC bio based?
IVERIC bio is headquartered in Princeton, United States, in the North America region.
How does IVERIC bio make money?
One revenue line is on record: pharmaceutical Product Sales.
Does IVERIC bio have an API?
No public API is recorded for IVERIC bio.
What industry is IVERIC bio in?
IVERIC bio's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its SIC code is 2836.